The results of Chen et al. suggest that GPx3 methylation is associated with chemotherapy resistance in head and neck cancer and can be used as a potential prognostic indicator for head and neck cancer patients receiving cisplatin-based chemotherapy (Chen et al., 2011). This evidence concerns the gene GPX3 and head and neck cancer.